On August 29, 2019 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, reported that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences (Press release, Kura Oncology, AUG 29, 2019, View Source [SID1234539110]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A panel discussion entitled "Focusing the Laser on Precision Oncology" at Citi’s 14th Annual Biotech Conference in Boston at 9:30 a.m. ET / 6:30 a.m. PT on September 5, 2019; and

An analyst-led discussion at H.C. Wainwright 21st Annual Global Investment Conference in New York at 12:50 p.m. ET / 9:50 a.m. PT on September 10, 2019.
A live audio webcast of both discussions will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available immediately following the event.